EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications

Shilpi Sarkar, Dheepika Venkatesh, Thirukumaran Kandasamy, Siddhartha Sankar Ghosh

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2908287 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Shilpi Sarkar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, 781039 Guwahati, Assam, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Epigenesis, Genetic, DNA Methylation, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Nanotechnology at IIT Guwahati.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer, a heterogeneous and intricate disease, ranks among the leading causes of mortality in women. Restricted therapeutic choices, drug resistance, recurrence, and metastasis are the predominant conditions that lead to mortality. Accumulating evidence has shown breast cancer initiation and progression happen through a multifaceted and intricate process that involves numerous genetic and epigenetic alterations. The modulation of gene expression through epigenetic modifications, encompassing DNA methylation, histone alterations, and non-coding RNA regulation, has emerged as a fascinating field that represents a new avenue for breast cancer therapy. This review emphasizes various aberrant epigenetic regulations implicated in the onset and advancement of breast cancer. The critical epigenetic modifications closely associated with estrogen signaling, epithelial-to-mesenchymal transition (EMT), cancer stemness, and drug resistance have been discussed extensively. Moreover, it highlights current epi-drugs, including DNA modifying agents, histone acetyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and histone demethyltransferase inhibitors used for breast cancer treatment. Nonetheless, we described current investigations pertaining to combination therapy employing epi-drugs and future challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEpigenesis, GeneticDNA MethylationEpithelial-Mesenchymal TransitionHumansFemaleDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHistonesAntineoplastic AgentsHistone Deacetylase Inhibitors

Stichwörter der Autor:innen

breast cancerdrug resistanceepidrugsepigeneticsepithelial-to-mesenchymal transition

Substanzen

HistonesAntineoplastic AgentsHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, 781039 Guwahati, Assam, India.
  • Centre for Nanotechnology, Indian Institute of Technology Guwahati, 781039 Guwahati, Assam, India.

Förderung

  • Centre for Nanotechnology at IIT Guwahati

Zitieren

APA

Sarkar, S., Venkatesh, D., Kandasamy, T., & Ghosh, S. S. (2024). Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2908287

Vancouver

Sarkar S, Venkatesh D, Kandasamy T, Ghosh SS. Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2908287

BibTeX
@article{Sarkar2024,
  author = {Sarkar, Shilpi and Venkatesh, Dheepika and Kandasamy, Thirukumaran and Ghosh, Siddhartha Sankar},
  title = {Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2908287}
}
Kostenlos starten →